Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer

Publication date: Available online 15 January 2020Source: Life SciencesAuthor(s): Zhi Zeng, Zi-yao Wang, Yu-kun Li, Dong-mei Ye, Juan Zeng, Jia-li Hu, Pi-feng Chen, Jiao Xiao, Juan Zou, Zhen-hua LiAbstractNuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) is a transcription factor that can regulate downstream target gene expression. Kelch-like ECH-associated protein 1 (Keap1) negatively regulates Nrf2 activation and translocation to target its 26S proteasomal degradation. It has been widely reported that the Keap1/Nrf2 pathway is associated with tumorigenesis, chemotherapy resistance and progression and development of non-small cell lung cancer (NSCLC). High expression of Nrf2 and low abundance of Keap1 contribute to the abnormalities and unrealistic treatment prognosis of NSCLC. Therefore, elucidating the role and potential mechanism of Nrf2 in NSCLC is essential for understanding tumorigenesis and for the development of strategies for effective clinical management. Here, we summarize current knowledge about the molecular structure and biological function of Nrf2, and we discuss the roles of Nrf2 in tumorigenesis, which will further provide a possible therapeutic strategy for NSCLC.Graphical abstract
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Hepatoma-Derived Growth Factor and DDX5 Promote Carcinogenesis and Progression of Endometrial Cancer by Activating β-Catenin Chunhua Liu1†, Lijing Wang1†, Qingping Jiang2†, Junyi Zhang3†, Litong Zhu1, Li Lin1, Huiping Jiang1, Dan Lin1, Yanyi Xiao1, Weiyi Fang1,3 and Suiqun Guo1* 1Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China 2Department of Pathology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 3Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guang...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to explore the role and mechanism of long noncoding RNA plasmacytoma variant translocation 1 (PVT1) in cisplatin sensitivity of NSCLC.MethodsPaired tumor and adjacent tissues were collected from forty patients with NSCLC. The clinical value of PVT1 was investigated according to clinicopathological parameters of patients. Cisplatin-sensitive or -resistant cells (A549 or A549/DDP) were used forin vitro experiments. Cell viability, apoptosis, autophagy and animal experiments were conducted to investigate cisplatin sensitivity. The expressions of PVT1, microRNA-216b (miR-216b) and apoptosis- or autophagy-relat...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
This study is registered at ClinicalTrials.gov, number NCT02220894.FindingsFrom Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years [IQR 57–69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median follow-up was 12·8 months. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50% hazard...
Source: The Lancet - Category: General Medicine Source Type: research
Lung cancer is the most common tumor and the leading cause of cancer-related death worldwide. Approximately 6.7% of non-small-cell lung cancers (NSCLCs) show anaplastic lymphoma kinase (ALK) rearrangement and could benefit from ALK-targeted treatment. Various anti-ALK drugs have been developed during the past years, but it is actually controversial which sequence and which ALK inhibitor is recommended for a single patient. Leptomeningeal carcinomatosis (LC) is associated with a poor prognosis, with an overall survival of 2–4 months for treated patients. The data about LC management derive mainly from retrospective st...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CASE REPORTS Source Type: research
Authors: Griesinger F, Roeper J, Pöttgen C, Willborn KC, Eberhardt WEE Abstract The progress in molecular biology has revolutionized systemic treatment of advanced non-small-cell lung cancer (NSCLC) from conventional chemotherapy to a treatment stratified by histology and genetic aberrations. Tumors harboring a translocation of the anaplastic-lymphoma-kinase (ALK) gene constitute a distinct genetic and clinico-pathologic NSCLC subtype with patients with ALK-positive disease being at a higher risk for developing brain metastases. Due to the introduction of effective targeted therapy with ALK-inhibitors, today, ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Standard-of-care first-line therapy for advanced non ―small-cell lung cancer (NSCLC) without sensitizing EGFR mutations or ALK translocation has historically been platinum-doublet chemotherapy with or without maintenance therapy [1]. Adding bevacizumab may improve outcomes in eligible patients with non-squamous histology albeit with added toxicity [ 1–4]; otherwise there has been limited evidence that addition of a third agent provides clinical benefit.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, this study revealed that distinct ALK translocation variants render similar clinical responsiveness to ALK inhibitors. PMID: 30071258 [PubMed - as supplied by publisher]
Source: Biochimie - Category: Biochemistry Authors: Tags: Biochimie Source Type: research
This study aimed to investigate the correlation between chemotherapy resistance and BCL9/Wnt/β-catenin signaling dysfunction.Main methodsWe performed BCL9 knockdown using a lentivirus-mediated sh-RNA interference in cisplatin-resistant (CR) lung cancer cells. Subsequently, the migration and invasion were determined by wound-healing and Transwell assays. Furthermore, EMT markers and β-catenin were examined by Western blot. Immunofluorescence was used to investigate the subcellular localization of β-catenin. The chemotherapeutic sensitivity to cisplatin in A549/DDP cell lines after treatment with BCL9 sh-RNA w...
Source: Life Sciences - Category: Biology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Translocation